Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | SCD | O00767 | 9/20 | 0.59 |
| ▸ | PPARA | Q07869 | 2/20 | 0.57 |
| ▸ | CDC7 | O00311 | 1/20 | 0.57 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.57 |
| ▸ | CDK2 | P24941 | 1/20 | 0.57 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12464767 | 0.88 | HPGD (0.67) | HPGDNPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL4294474 | 0.88 | HPGD (0.63) | HPGDNPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL13541886 | 0.80 | MAOB (0.58) | HPGDNPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL17704560 | 0.80 | PPARA (0.66) | HPGDNPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3455194 | 0.79 | SCD (0.56) | SCD | |
| SCHEMBL29071267 | 0.79 | KMT2A (0.74) | HPGDNPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL30659931 | 0.79 | KMT2A (0.74) | HPGDNPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL27630594 | 0.77 | HPGD (0.55) | HPGDNPC1SMN1; SMN2ALDH1A1GAA | |
| SCHEMBL3586148 | 0.77 | SCD (0.73) | HPGDNPC1SMN1; SMN2ALDH1A1SCD | |
| SCHEMBL28449044 | 0.77 | HPGD (0.76) | HPGDNPC1SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110184027-A1 | TISSUE SELECTIVE STEAROYL-COA DESATURASE 1 INHIBITORS AND CELL BASED SCREENING ASSAY FOR THEIR IDENTIFICATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184027-A1 | TISSUE SELECTIVE STEAROYL-COA DESATURASE 1 INHIBITORS AND CELL BASED SCREENING ASSAY FOR THEIR IDENTIFICATION | SCD, SCD5, CPT1B | HPGD 710/4885NPC1 225/4885SMN1; SMN2 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.